Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma

被引:46
作者
Huang, SP
Wu, MS
Wang, HP
Yang, CS
Kuo, ML
Lin, JT
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei 100, Taiwan
[3] En Chu Kong Hosp, Dept Internal Med, Taipei, Taiwan
[4] Natl Taiwan Univ, Inst Toxicol, Taipei 10764, Taiwan
关键词
angiogenesis; gastric carcinoma; interleukin-6; vascular endothelial growth factor;
D O I
10.1046/j.1440-1746.2002.02873.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim: Vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) are associated with the disease status of gastric carcinoma. However, their relationship remains unclear. This study aims to determine and correlate serum levels of VEGF and IL-6 in gastric carcinoma. Methods: A total of 107 patients receiving gastrectomy entered this study. Serum levels of VEGF and IL-6 were measured by using ELISA, and were analyzed by using the Student's t-test to compare means and by Pearson correlation analysis to calculate correlation coefficients with respect to pathological characteristics including depth of tumor invasion, Lauren's classification, tumor location, Borrmann classification, and the status of lymph node metastasis. Results: Serum VEGF levels were significantly higher in patients with mixed type carcinoma (387.5 +/- 176.9 vs 255.3 +/- 154.1 pg/mL, P = 0.047) or lymph node metastasis (339.1 +/- 205.1 vs 223.2 +/- 197.4 pg/mL, P = 0.007). Serum IL-6 levels were significantly higher in patients with Borrmann type IV carcinoma, compared with Borrmann type II and III carcinoma. In general, no correlation was noted between serum VEGF levels and IL-6 levels (r = 0.142, P = 0.145), but significant correlation was found in patients with early gastric carcinoma (r = 0.627, P = 0.004) or mixed type carcinoma (r = 0.804, P = 0.016). Conclusions: This study supports the correlation between serum VEGF and IL-6 levels in distinct subsets of gastric carcinoma patients, and indicates that IL-6 may play a role for the angiogenesis of gastric carcinoma via modulation of VEGF. (C) 2002 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:1165 / 1169
页数:5
相关论文
共 33 条
[1]   SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].
BATAILLE, R ;
JOURDAN, M ;
ZHANG, XG ;
KLEIN, B .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011
[2]   SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER [J].
BEREK, JS ;
CHUNG, C ;
KALDI, K ;
WATSON, JM ;
KNOX, RM ;
MARTINEZMAZA, O .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) :1038-1043
[3]   Interleukin 6 induces the expression of vascular endothelial growth factor [J].
Cohen, T ;
Nahari, D ;
Cerem, LW ;
Neufeld, G ;
Levi, BZ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) :736-741
[4]   TUMOR VASCULAR-PERMEABILITY FACTOR STIMULATES ENDOTHELIAL-CELL GROWTH AND ANGIOGENESIS [J].
CONNOLLY, DT ;
HEUVELMAN, DM ;
NELSON, R ;
OLANDER, JV ;
EPPLEY, BL ;
DELFINO, JJ ;
SIEGEL, NR ;
LEIMGRUBER, RM ;
FEDER, J .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1470-1478
[5]   Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator [J].
De Vita, F ;
Romano, C ;
Orditura, M ;
Galizia, G ;
Martinelli, E ;
Lieto, E ;
Catalano, G .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (01) :45-52
[6]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[7]  
Fontanini G, 1997, CLIN CANCER RES, V3, P861
[8]   Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes [J].
Funamoto, M ;
Fujio, Y ;
Kunisada, K ;
Negoro, S ;
Tone, E ;
Osugi, T ;
Hirota, H ;
Izumi, M ;
Yoshizaki, K ;
Walsh, K ;
Kishimoto, T ;
Yamauchi-Takihara, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (14) :10561-10566
[9]   BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6 [J].
HIRANO, T ;
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
IMMUNOLOGY TODAY, 1990, 11 (12) :443-449
[10]  
Inoue K, 1997, CANCER, V79, P206, DOI 10.1002/(SICI)1097-0142(19970115)79:2<206::AID-CNCR2>3.0.CO